Daniel Wermeling - Pharm.D., FASHP

Dr. Wermeling's primary area of research involves formal drug development in an academic setting sponsored by pharmaceutical industry, University/faculty sponsorship, or of products of his own design. A goal for this development process, particularly for UK-held intellectual property, is to evolve the development into independent businesses that form in the Lexington community. Specific development programs include the design, formulation, manufacturing and clinical testing of drugs and delivery systems designed for intranasal drug administration leading toward a new drug application and FDA approval for marketing. Dr. Wermeling holds several research agreements that use the University as the principal source of research and development resources.

Selected Honors

• Kentucky Colonel (2006)
• Kentucky Research Pharmacist of the Year (1988)

Teaching Activities

• Module Leader, PHR 946 Advanced Therapeutics I - Pain Management Module
• Coordinator, PHR 564 Introduction to FDA and Drug Development Process
• Coordinator, PHR 763 Drug Development Regulation and Clinical Research

Selected Publications/Presentations

• Pharmacokinetics and Pharmacodynamics of a New Intranasal Midazolam Formulation in Healthy Volunteers. Wermeling DP, Record K, Kelly TH, Archer SM, Clinch T, Rudy AC. Anesthesia and Analgesia. In press, 2006
• Ziconotide Infusion for Severe Chronic Pain: A Case Series of Patients with Neuropathic Pain. Wermeling DP, Berger JR., Pharmacotherapy 2006: 26 (3), 395-402.
• Pharmacokinetics, Bioequivalence and Dose Reproducibility of Intranasal Butorphanol After Administration with Two Different Nasal Spray Pumps. Wermeling DP, Miller JL, Archer SM, Rayens MK, Rudy AC., Journal of Clinical Pharmacology August 2005; 45 (8): 969-73.
• A Review of Ziconotide, an N-Type Calcium Channel Antagonist, Delivered by Intrathecal Adminsitration for the Treatment of Chronic Pain. Wermeling, DP. Pharmacotherapy 2005: 25 (8) 1084-94.
• A Randomized, Double-Blind, Parallel-Group Study Comparing the Analgesic Effects of Intranasal Butorphanol Tartrate to Placebo, Using a Unit Dose Nasal Spray Device, in the Dental Impaction Pain Model. Wermeling, DP, Grant GM, Lee A, Alexander N, Rudy AC. Clinical Therapeutics 2005; 27 (4): 430-440.
• Bioavailability of Intranasal Butorphanol Administered from a Single-dose Sprayer. Davis GA, Rudy A, Archer SM, Wermeling, DP. American Journal of Health System Pharmacy 2005 62 (1): 48-53
• Intranasal Delivery of recombinant human parathyroid hormone hPTH 1-34, teripartitide in rats. Agu R, Valiveti S, earles DC, Klausner M, Hayden PJ, Wermeling DP, Stinchcomb AL. Endocrine Research 2004; 30 (3), 455-467
• "Pharmacokinetics of Butorphanol Tartrate Administered from Single-Dose Intranasal Sprayer", Davis GA, Rudy AC, Archer SM, Wermeling DP, American Journal of Health-Systems Pharmacists 2004;61:261-266
• "Effect of Fluticasone Propionate Nasal Spray on Bioavailability of Intranasal Hydromorphone Hydrochloride in Patients with Allergic Rhinitis", Davis GA, Rudy AC, Archer SM, Wermeling DP, McNamara PJ, Pharmacotherapy 2004;24(1):26-32
• "Pharmacokinetics and Pharmacodynamics of Intrathecal Ziconotide in Chronic Pain Patients", Wermeling DP, Drass M, Ellis D, Mayo M, McGuire D, O'Connell D, Hale V, Chao S, The Journal of Clinical Pharmacology 2003;43:624-636
• "Hydromorphone Transfer Into Breast Milk After Intranasal Administration", Edwards JE, Rudy AC, Wermeling DP, Desai N, McNamara PJ, Pharmacotherapy 2003;23(2):153-158
• "Pharmacokinetics and Bioavailability of Single-Dose Intranasal Hydromorphone Hydrochloride in Healthy Volunteers", Coda BA, Rudy AC, Archer SM, Wermeling DP, Anesthesia and Analgesia 2003;97:117-123

Selected Grants

• 1R41AA016500-01, Priority Score 161, Nasal Delivery of Naltrexone for the Treatment of Alcoholism: Role: Principal Investigator 10% effort. National Institute on Alcoholism and Alcohol Abuse, $ 100,000, June 2006.
• The Effects of Intranasal Corticotropin Releasing Hormone on Cortical and Subcortical Information Processing. PI Royce Lee, M.D. $ 1000 per year for 2 years. Role - Co-Investigator on grant from Brain Foundation and subcontract from University of Illinois Chicago. April 2006.
• A Pilot Study of the Effect of Intranasal Corticotropin-Releasing Hormone on Emotion Processing in Remitted Depression. PI: Royce Lee, M.D. $ 30,000 over 2 years. Role - Co-investigator $ 3000/yr. NARSAD Foundation and University of Illinois subcontract. April 2006.
• Microneedle Assisted Naltrexone Hydrochloride Transdermal Delivery for the Treatment of Addictions. Role: Principal Investigator. UK Internal Competition. Pilot Research Project $17,250. April 2006.
• A Double Blind, Randomized, Placebo-Controlled, Parallel Study to Investigate the Safety, Tolerability and Pharmacokinetics of Multiple Oral Doses of GW572016 in Healthy Volunteers, Glaxo EFG10002 (Co-Principal Investigator) $671,627 2000 .
• ITI Infrastructure, Project #4 (DPEU). Inhalation Technology, Inc. (Principal Investigator) $2,177,587 2000-1 .
• A Single-Dose, Open-Label, Three Way Crossover, Randomized, Pilot Bioavailability Study of Lorazepam Comparing Intranasal Administration to Intravenous and Intramuscular Administration in Healthy Human Volunteers, Inhalation Technology, Inc. (Principal Investigator) $116,174 2000.
• A Double Blind, Randomized, Placebo-Controlled, Crossover Study to Investigate the Safety, Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GW572016 Ditosylate Monohydrate in Healthy Volunteers, Glaxo EFG10001(Co-Principal Investigator) $379,970 1999.
• "A Single and Multiple Dose Pharmacokinetic Study of 2.0 mg Intranasal Hydromorphone Hydrochloride in Healthy Volunteers, Inhalation Technology, Inc. (Principal Investigator) $160,896 1998 .